Anika Therapeutics
ANIK
120 hedge funds and large institutions have $376M invested in Anika Therapeutics in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 46 reducing their positions, and 17 closing their positions.
7,217% more call options, than puts
Call options by funds: $2.12M | Put options by funds: $29K
5% more capital invested
Capital invested by funds: $360M → $376M (+$16.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.38% less ownership
Funds ownership: 89.71% → 89.32% (-0.38%)
4% less funds holding
Funds holding: 125 → 120 (-5)
15% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 46
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
Top Buyers
| 1 |
CP
Caligan Partners
New York
|
+$3.68M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$3.56M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$2.04M |
| 4 |
Morgan Stanley
New York
|
+$2.03M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.53M |
Top Sellers
ANIK Hedge Fund Activity: Q1 2023 in Review
120 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2023, worth a combined $376M — up 4.6% from $360M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ANIK and 13 opened new positions — a net loss of 4 holders — while 46 trimmed existing stakes and 39 added.
The largest buyer was Caligan Partners, adding an estimated $3.68M. The largest seller was Ranger Investment Management, exiting entirely with an estimated $4.15M sold.
- 120 institutional investors held Anika Therapeutics (ANIK) as of Q1 2023, down from 125 in Q4 2022.
- Funds reported $376M of Anika Therapeutics stock for Q1 2023, up 4.6% quarter-over-quarter.
- 13 funds opened new Anika Therapeutics positions in Q1 2023 and 17 closed out, a net change of -4 holders.
- The largest Anika Therapeutics buyer in Q1 2023 was Caligan Partners, an estimated $3.68M added.
- The largest Anika Therapeutics seller in Q1 2023 was Ranger Investment Management, an estimated $4.15M sold.
Based on aggregated 13F filings for Q1 2023.